Sensitivity to the EGFR inhibitor, cetuximab, has been shown to require intact E-cadherin expression and silencing of E-cadherin by RNA interference was reported to reduce responsiveness to EGFR inhibition in previously sensitive bladder cancer cell lines [48]. This evidence concerns the gene CDH1 and urinary bladder cancer.